Joint supplements including glucosamine, chondroitin, and omega-3 fatty acids are widely used in dogs with osteoarthritis, with varying evidence of efficacy and clear welfare implications when effective.
The welfare dimension of joint supplements relates to the enormous prevalence of osteoarthritis in dogs and the chronic pain this condition causes. If supplements provide meaningful pain relief or slow disease progression, they represent a welfare benefit of significant scale given the number of dogs affected. The evidence base is genuinely mixed; some well-designed studies show benefits while others do not. The variation may reflect product quality differences, dosing inconsistencies, and individual variation in response. The most evidence-supported approach for dogs with confirmed osteoarthritis combines veterinary pain management with omega-3 supplementation from quality fish oil sources and appropriate body weight management, as obesity substantially worsens osteoarthritis welfare outcomes. Supplement use should complement rather than substitute for proper veterinary assessment and treatment.